November 2025 in “Open Repository of the University of Porto (University of Porto)” Continuous use of finasteride and minoxidil is effective for treating androgenetic alopecia.
1 citations
,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
39 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce symptoms in male Tourette syndrome patients.
2 citations
,
September 2011 in “Chiang Mai Medical Journal - เชียงใหม่เวชสาร” The generic finasteride is equivalent to the original.
152 citations
,
October 2010 in “Archives of Dermatology” Finasteride helps hair growth but may cause sexual side effects.
11 citations
,
December 2018 in “Journal of Dermatology” Finasteride effectively treats hair loss in Korean men for at least 5 years, with V type responding better.
42 citations
,
December 2007 in “American Journal of Psychiatry” Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
September 1997 in “Journal of The European Academy of Dermatology and Venereology” New treatment improves male hair loss.
Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
Finasteride's effects on prostate cancer are not clear from this text.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
January 2000 in “Annals of Dermatology” Finasteride effectively treats hair loss in men with minimal side effects.
March 2023 in “Enciclopédia Biosfera” Finasteride effectively treats BPH but requires continuous use to maintain benefits.
November 2013 in “Annales de Dermatologie et de Vénéréologie”
6 citations
,
August 2005 in “The Journal of Clinical Endocrinology & Metabolism” Finasteride causes temporary cell death in BPH tissues.
45 citations
,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
6 citations
,
October 2012 in “PubMed” The combined treatment of 3% minoxidil and 0.1% finasteride is more effective in improving hair loss than 3% minoxidil alone, with similar side effects.
26 citations
,
April 2002 in “Archives of Dermatology”
5 citations
,
December 2012 in “PubMed” Stopping the use of the drug finasteride can improve sperm count and does not prevent normal conception, but caution is advised when trying to conceive.
10 citations
,
January 2017 in “Skin Pharmacology and Physiology” Finasteride may cause vitiligo, sexual issues, and depression; better treatments and predicting side effects needed.
October 2013 in “Handbook of Metabolic Pathways of Xenobiotics” Finasteride is mostly broken down in the body and excreted in urine and feces.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
24 citations
,
January 2006 in “Skin Pharmacology and Physiology” Finasteride reverses early hair loss and promotes growth.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.